Definitive Contract HDTRA114C0017
Award Date 1/27/14
Potential Completion Date 6/30/15
Potential Value $511K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost Plus Fixed Fee
Place of Performance
Denmark
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
7
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $1,628,690,592.00 definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Bavarian Nordic A/S, a for-profit biotechnology company based in Denmark. The contract has a firm fixed price pricing type and an ultimate completion date of September 26, 2027. It is not a set-aside contract. Bavarian Nordic A/S is providing the government with various goods and services, including endpoint titer analysis services involving...
- This federal contract award is for operations research and quantitative services delivered by Bavarian Nordic A/S, a biotechnology company focused on cancer immunotherapies and infectious disease vaccines. The $29,216,666 definitive contract was awarded on February 14, 2003 by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, with a completion date of September 30, 2009. The contract does not have a set-aside designation. Bavarian Nordic has provided various...
- This is a federal contract award from the Defense Threat Reduction Agency (DTRA), a defense agency, to Sanofi Pasteur Vaxdesign Corp, a for-profit foreign-owned organization. The contract is a Cost Plus Fixed Fee Definitive Contract with a ceiling value of $10,779,939.95 and an ultimate completion date of March 24, 2018. The contract was awarded on March 21, 2013 and does not have a set-aside designation. The contract is for the BASE YEAR, indicating it may be part of a larger contract...
- This is a Cost Plus Fixed Fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS), to Sanofi Pasteur Biologics, LLC for the production and testing of a Modified Vaccinia Ankara (MVA) vaccine. The contract award has a ceiling value of $74,940,566.62 and an ultimate completion date of February 6, 2015. The contract is not designated as a set-aside. As a child company of the Sanofi group, Sanofi...
- This federal contract award, valued at $28,836,234.91, was issued by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation. The contract is for stability testing of the RF1V plague vaccine and RBV A/B botulism vaccine drug products, drug substances, reference materials, and other critical reagents. The effort involves ongoing stability testing, reporting, and...
- This is a federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to IDT Biologika GMBH, a foreign-owned, for-profit biotechnology company based in Germany. The contract is a $70,108.14 delivery order under a larger indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle for manufacturing and characterization services for vaccines and other biologics for infectious diseases. The...
- This is a fixed-price delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to IDT Biologika GMBH, a German biotechnology company. The contract is for the manufacturing of master cell banks to support COVID-19 pandemic preparedness efforts. The base award is for $20,462.00, with a total potential ceiling value of $554,341.00. The contract has an ultimate completion date of May 17, 2025,...
- This federal contract award, valued at $1,802,359.68, was made by the Defense Threat Reduction Agency (DTRA) to the University of South Alabama (USA) for the development of "antigenically defined vaccines for immunization against melioidosis and glanders." This is a definitive, cost-type contract with no set-aside designation. The University of South Alabama has extensive experience in executing federal contracts and grants, and this award is part of a larger $146.3 million...
- This is a $3,947,011.00 cost-plus-fixed-fee delivery order contract awarded by the Defense Threat Reduction Agency (DTRA) to the Ministry of Defence (MOD) of the United Kingdom, operating as the Defence Science and Technology Laboratory (DSTL). The contract is for a research and development effort focused on using virus-like particles as a novel platform for delivering protective antigens against Burkholderia bacteria. The contract does not have a set-aside designation. DSTL is a...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded Battelle Memorial Institute a $20.4 million delivery order contract on September 15, 2003, for the development of a Bacillus anthracis spore challenge model and performance studies using the rPA (recombinant protective antigen) vaccine. The contract, which operated on a cost-plus-fixed-fee basis through September 30, 2012, was issued with no set-aside designation, reflecting open competition for this specialized scientific...